Australia has revived the national debate over whether biological medicines should have special identification requirements, mainly as a result of the US decision to introduce the use of suffixes for all reference biologics and their biosimilar versions.
On July 28, the Australian Therapeutic Goods Administration launched a stakeholder consultation on a range of options for...






